ClassID:

170370

G01N2333/4704 - CPC Classification

Classification description:

Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates; Assays involving proteins of known structure or function as defined in the subgroups; Details; Regulators; Modulating activity Inhibitors; Supressors

Recent Application in this class:
#1
20260098868
2026-04-09

BIOMARKERS IN LONG-COVID-19

#2
20260092931
2026-04-02

Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia

#3
20260086094
2026-03-26

BIOMARKER PANEL, MICROFLUIDIC DEVICE AND DETECTION KIT FOR CAPTURING CIRCULATING TUMOR CELLS

#4
20260063637
2026-03-05

BIOMARKERS FOR DETECTING AND MONITORING BREAST CANCER

#5
20260056213
2026-02-26

EXTRACELLULAR VESICLES-BASED BIOMARKERS FOR PANCREATIC CANCER

#6
20260055460
2026-02-26

MARKERS OF TOTIPOTENCY AND METHODS OF USE

#7
20250381183
2025-12-18

TARGETING S100A9-ALDH1A1-RETINOIC ACID SIGNALING TO SUPPRESS BRAIN RELAPSE IN EGFR-MUTANT LUNG CANCER

#8
20250369986
2025-12-04

APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS

#9
20250327804
2025-10-23

Methods and Compositions for Oral Cancer Risk

#10
20250320559
2025-10-16

METHODS RELATING TO IMPAIRED RESPIRATORY HEALTH THERAPEUTICS

#11
20250302981
2025-10-02

NOVEL USE OF ANTICANCER AGENT PRODRUG CONJUGATE

#12
20250277799
2025-09-04

PHOSPHO-TAU ANTIBODIES AND METHODS OF USE

#13
20250180557
2025-06-05

ORAL MESENCHYMAL STEM CELLS AND USE THEREOF

#14
20250154599
2025-05-15

NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF

#15
20250154592
2025-05-15

Methods and Compositions for Evaluating Biomarkers in Salivary Exosomes and Evaluating Cognitive Fatigue

#16
20250123294
2025-04-17

METHODS AND DEVICES FOR DETECTION OF ORTHOGONAL CLASSES OF DISEASE BIOMARKERS

#17
20250116676
2025-04-10

PHOSPHOPEPTIDE/PHOSPHOPROTEIN SIGNATURE PREDICTING BASAL-LIKE BREAST CANCER RECURRENCE

#18
20250093370
2025-03-20

BIOMARKERS AND THEIR USE IN DIAGNOSING PARKINSON'S DISEASE, VITREORETINAL DISEASES, AND AGE-RELATED PATHOLOGIES

#19
20240425865
2024-12-26

METHODS FOR TREATING CELLULAR INFLAMMATION INDUCED BY AFB1

#20
20240369575
2024-11-07

ANTI-POLYUBIQUITIN MULTISPECIFIC ANTIBODIES

#21
20240360206
2024-10-31

PHOSPHO-TAU ANTIBODIES AND METHODS OF USE

#22
20240358858
2024-10-31

COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING AGE-RELATED CONDITIONS

#23
20240353428
2024-10-24

Phospho-TAU antibodies and methods of use

#24
20240344133
2024-10-17

A METHOD OF PREDICTING RISK OF AN AGGRESSIVE OR RECURRENT CANCER

#25
20240209075
2024-06-27

Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization

#26
20240091247
2024-03-21

INHIBITOR FOR CHRONIC MYELOID LEUKEMIA STEM CELLS

#27
20240043939
2024-02-08

NUCLEIC ACID BIOMARKER AND USE THEREOF

#28
20230305023
2023-09-28

METHODS OF TREATMENT AND DIAGNOSTIC OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH INTENSE STRESS

#29
20230288432
2023-09-14

TDP-43 BIOSENSOR CELL LINES

#30
20230221322
2023-07-13

METHOD AND REAGENT FOR DETECTING PANCREATIC CANCERS

#31
20230212680
2023-07-06

NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF

#32
20230184785
2023-06-15

DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA

#33
20230176073
2023-06-08

Assays and methods for targeted treatment of hydrosalpinx

#34
20230133528
2023-05-04

METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS

#35
20230122642
2023-04-20

METHOD AND REAGENT FOR DETECTING MALIGNANT OVARIAN TUMORS

#36
20220267743
2022-08-25

HSD17B13 variants and uses thereof

#37
20220204599
2022-06-30

NOVEL CTHRC1-SPECIFIC ANTIBODY AND USE THEREOF

#38
20220146529
2022-05-12

IMMUNOASSAY METHOD FOR FREE AIM IN BIOLOGICAL SAMPLE

#39
20220099684
2022-03-31

Inter-alpha inhibitor proteins

#40
20220003768
2022-01-06

SEROLOGICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG CANCER

#41
20220003749
2022-01-06

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

#42
20210396736
2021-12-23

SCREENING ASSAY

#43
20210389326
2021-12-16

METHOD FOR DETECTING VIRAL LIVER CANCER

#44
20210380671
2021-12-09

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#45
20210349089
2021-11-11

Biomarkers for the diagnosis of invasive fungal infections

#46
20210311022
2021-10-07

METHODS, KITS AND COMPOSITIONS FOR CHARACTERIZING AN ANTI-INFLAMMATORY RESPONSE OF A PRODUCT

#47
20210270808
2021-09-02

METHODS OF DETERMINING INTERFERON HAVING DIRECT INHIBITORY EFFECTS ON TUMORS AND USES THEREOF

#48
20210231670
2021-07-29

METHODS OF EVALUATING TREATMENT OUTCOME IN HIGH GRADE SEROUS OVARIAN CANCER

#49
20210139982
2021-05-13

MARKERS OF TOTIPOTENCY AND METHODS OF USE

#50
20210033628
2021-02-04

DIAGNOSTIC AND DRUG SCREENING FOR MOLECULAR SIGNATURES OF EARLY ONSET SPORADIC PARKINSON'S DISEASE

#51
20210032302
2021-02-04

METHOD FOR DETECTING AN ANTIGEN-SPECIFIC ANTIBODY AND REAGENT FOR USE THEREIN

#52
20210023039
2021-01-28

PKC PATHWAY IN PARKINSON'S DISEASE

#53
20210018515
2021-01-21

BIOMARKER COMBINATION FOR IDENTIFICATION OF "AT-RISK" SUBJECTS FOR AKI

#54
20200282010
2020-09-10

IMMUNOGENIC COMPOSITIONS AND USES THEREFOR

#55
20200255831
2020-08-13

miRNA biogenesis in exosomes for diagnosis and therapy

#56
20200231664
2020-07-23

Antibodies specific for sclerostin and methods for increasing bone mineralization

#57
20200140954
2020-05-07

Nucleic acid biomarker and use thereof

#58
20200057077
2020-02-20

METHODS FOR QUANTIFYING INTER-ALPHA INHIBITOR PROTEINS

#59
20200041527
2020-02-06

Neurofibromin/dopamine signaling as a biomarker for cognitive and behavioral problems in children with neurofibromatosis type 1 (NF1 )

#60
20200032354
2020-01-30

NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOF

#61
20200024668
2020-01-23

Tumor suppressor REC8 as a biomarker for gastric cancer

#62
20190369121
2019-12-05

System and method for detection of trauma

#63
20190352380
2019-11-21

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#64
20190346457
2019-11-14

ASSAYS AND METHODS FOR DETECTION AND TARGETED TREATMENT OF HYDROSALPINX

#65
20190302120
2019-10-03

Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas

#66
20190298798
2019-10-03

Trefoil family factor proteins and uses thereof

#67
20190242902
2019-08-08

Kisspeptin-54 detection by tandem mass spectrometry

#68
20190178866
2019-06-13

SRM/MRM assay for the cyclin-dependent kinase inhibitor 2A (p16) protein

#69
20190154691
2019-05-23

METHOD FOR QUANTITATIVE ASSESSMENT IN BIOLOGICAL SAMPLE OF THE PHOSPHORYLATED AND NON-PHOSPHORYLATED FORM OF RKIP

#70
20190145983
2019-05-16

Analysis of amino acids in body fluid by liquid chromotography-mass spectrometry

#71
20190137517
2019-05-09

BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

#72
20190064172
2019-02-28

PROGNOSIS OF SEROUS OVARIAN CANCER USING BIOMARKERS

#73
20190033323
2019-01-31

Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure

#74
20190004033
2019-01-03

Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers

#75
20180372756
2018-12-27

TDP-43 in degenerative disease

#76
20180334720
2018-11-22

Tumor suppressor REC8 as a biomarker for gastric cancer

#77
20180306796
2018-10-25

Methods and compositions relating to proteasome inhibitor resistance

#78
20180284132
2018-10-04

KITS FOR STRATIFYING SCOLIOTIC SUBJECTS

#79
20180258171
2018-09-13

Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof

#80
20180224455
2018-08-09

Using phage epitopes to profile the immune response

#81
20180217162
2018-08-02

Biomarkers of myocardial injury

#82
20180216084
2018-08-02

HSD17B13 variants and uses thereof

#83
20180177825
2018-06-28

Methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy

#84
20180172693
2018-06-21

BIN1 expression as a marker of cancer

#85
20180164291
2018-06-14

Methods of determining interferon having direct inhibitory effects on tumors and uses thereof

#86
20180164286
2018-06-14

Cell-based assay for determining mTOR activity

#87
20180149662
2018-05-31

Kisspeptin-54 detection by tandem mass spectrometry

#88
20180119233
2018-05-03

Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof

#89
20180072801
2018-03-15

ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION

#90
20180064828
2018-03-08

Methods for the diagnosis and treatment of Sjögren's syndrome

#91
20180045729
2018-02-15

Mutant smoothened and methods of using the same

#92
20180037649
2018-02-08

CKAP4-molecular-targeted antitumor agent

#93
20180030546
2018-02-01

Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors

#94
20170349631
2017-12-07

Methods of selecting compstatin mimetics

#95
20170321282
2017-11-09

IMPROVED TREATMENTS OF CANCER RESISTANT TO TAXOIDS

#96
20170315134
2017-11-02

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

#97
20170314077
2017-11-02

SLFN11 AS BIOMARKER FOR AML

#98
20170298109
2017-10-19

Tumor antigen peptide

#99
20170283875
2017-10-05

Biomarker FOXF2 for gastric cancer

#100
20170268067
2017-09-21

Use of EI24 gene

#101
20170219608
2017-08-03

Kit for rapidly testing myocardial infarction and a preparation method and an application thereof

#102
20170157211
2017-06-08

Trefoil family factor proteins and uses thereof

#103
20170081380
2017-03-23

Method of treating BCL-2 over-expressing disorders using arts containing a BH3-like domain

#104
20170049800
2017-02-23

Pharmaceutical combination comprising a CIP2A silencing agent for use in the treatment of a hyperproliferative disorder, preferably one with impaired P53 function

#105
20170030927
2017-02-02

METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE

#106
20160370383
2016-12-22

NEUROFIBROMIN/DOPAMINE SIGNALING AS A BIOMARKER FOR COGNITIVE AND BEHAVIORAL PROBLEMS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1)

#107
20160363599
2016-12-15

Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders

#108
20160347836
2016-12-01

TREATMENT OF HODGKIN'S LYMPHOMA USING AN ANTI-PD-1 ANTIBODY

#109
20160341713
2016-11-24

SRM/MRM assay for the cyclin-dependent kinase inhibitor 2A (p16) protein

#110
20160320398
2016-11-03

SRM/MRM assay for subtyping lung histology

#111
20160313300
2016-10-27

METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS

#112
20160299155
2016-10-13

Methods for diagnosing osteoarthritis

#113
20160299142
2016-10-13

Semaphorin 3A as a diagnostic marker for urothelial cancer

#114
20160289770
2016-10-06

MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS

#115
20160258934
2016-09-08

Proteasome inhibition assay and methods of use

#116
20160245804
2016-08-25

Methods, Systems and Kits of Fecal NGal Rapid Immunochromatographic Test

#117
20160202264
2016-07-14

A high-throughput assay to identify molecules that modulate Rb-E2F binding

#118
20160199445
2016-07-14

USE OF ARPIN A NEW INHIBITOR OF THE ARP2/3 COMPLEX FOR THE DIAGNOSIS AND TREATMENT OF DISEASES

#119
20160154011
2016-06-02

Dickkopf (DKK) Proteins as Biomarkers for Cognitive Decline Associated with Alzheimer's Disease

#120
20160153996
2016-06-02

B7-H1 AND B7-H4 IN CANCER

#121
20160146815
2016-05-26

METHOD FOR SCREEING CANCER METASTASIS INHIBITOR USING CULTURE OF CELLS OR SPHEROIDICALLY AGGREGATED CELLS IN WHICH LYSYL-TRNA SYNTHETASE IS REGULATED TO BE EXPRESSED OR UNEXPRESSED

#122
20160139146
2016-05-19

GI PROTEIN PHOSPHORYLATION AS MARKER FOR SCOLIOSIS AND SCOLIOSIS PROGRESSION, METHODS OF INCREASING GIPCR SIGNALING IN SCOLIOTIC SUBJECTS

#123
20160123995
2016-05-05

Biomarker of rehospitalization after heart failure

#124
20160109450
2016-04-21

METHOD FOR MONITORING METASTASIS OF CANCER CELLS USING CELLS CULTURED IN THREE DIMENSIONAL COLLAGEN ENVIRONMENT

#125
20160091504
2016-03-31

Methods for diagnosis and treatment of amyotrophic lateral sclerosis based on an increased level of interaction between TDP-43 polypeptide and NF-KB P65 polypeptide

#126
20160061832
2016-03-03

Biomarkers for inflammatory bowel disease with ankylosing spondylitis

#127
20160054336
2016-02-25

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#128
20160054323
2016-02-25

SRM/MRM assay for subtyping lung histology

#129
20160046701
2016-02-18

COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY

#130
20160041174
2016-02-11

Using phage epitopes to profile the immune response

#131
20160031958
2016-02-04

METHODS AND COMPOSITIONS USEFUL IN MANIPULATING THE STABILITY OF RE1 SILENCING TRANSCRIPTION FACTOR

#132
20160025729
2016-01-28

Systems And Methods For Early Detection Of Cervical Cancer By Multiplex Protein Biomarkers

#133
20160024503
2016-01-28

miRNA BIOGENESIS IN EXOSOMES FOR DIAGNOSIS AND THERAPY

#134
20160022617
2016-01-28

Treatment of insulin resistance associated with prolonged physical inactivity

#135
20160015702
2016-01-21

Aminoheteroaryl compounds as MTH1 inhibitors

#136
20160015665
2016-01-21

Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment

#137
20160011197
2016-01-14

Methods and Compositions for the Diagnosis of a Thyroid Condition

#138
20160000866
2016-01-07

CTHRC1 RECEPTOR AND METHODS OF USE THEREOF

#139
20160000735
2016-01-07

Methods for classifying a cancer as susceptible to TMEPAI-directed therapies and treating such cancers

#140
20150368726
2015-12-24

Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof

#141
20150344968
2015-12-03

METHODS FOR DETERMINING PARP INHIBITOR AND PLATINUM RESISTANCE IN CANCER THERAPY

#142
20150329914
2015-11-19

PREDICTIVE BIOMARKERS FOR PRE-MALIGNANT BREAST LESIONS

#143
20150329913
2015-11-19

Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors

#144
20150309012
2015-10-29

ANTI-MIF ANTIBODY CELL MIGRATION ASSAY

#145
20150307573
2015-10-29

CYLINDRINS AS ETIOLOGIC AGENTS OF AMYLOID DISEASES

#146
20150297676
2015-10-22

COMPOSITION COMPRISING GRIM-19 AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING OBESITY OR LIPID-RELATED METABOLIC DISEASES

#147
20150285810
2015-10-08

iASPP phosphorylation and metastatic potential

#148
20150276755
2015-10-01

METHODS FOR DETERMINING RESISTANCE AGAINST MOLECULES TARGETING PROTEINS

#149
20150273083
2015-10-01

Methods for the diagnosis and treatment of sjögren's syndrome

#150
20150258147
2015-09-17

Isolated cardiac stem cells and methods of their use

#151
20150253342
2015-09-10

Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer

#152
20150247869
2015-09-03

MARKER ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS

#153
20150216929
2015-08-06

Semaphorin 3A for treatment and assessment of severity of Asthma

#154
20150212086
2015-07-30

Diagnosis and treatment of brain tumor

#155
20150204869
2015-07-23

Lipocalin-2 as a Biomarker for Pneumococcal Infection Status and Uses Thereof

#156
20150197818
2015-07-16

Biomarkers for subtypes of cervical cancer

#157
20150191537
2015-07-09

Antibodies specific for sclerostin and methods for increasing bone mineralization

#158
20150184245
2015-07-02

Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof

#159
20150177250
2015-06-25

DETERMINATION OF EFFICIENT TIME(S) FOR CHEMOTHERAPY DELIVERY

#160
20150168399
2015-06-18

MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT

#161
20150160230
2015-06-11

Methods of predicting and decreasing the risk of pre-term birth

#162
20150159131
2015-06-11

METHODS AND COMPOSITIONS FOR REGULATING MUSASHI FUNCTION

#163
20150152508
2015-06-04

NUCLEIC ACID BIOMARKER AND USE THEREOF

#164
20150150940
2015-06-04

TREFOIL FAMILY FACTOR PROTEINS AND USES THEREOF

#165
20150115150
2015-04-30

Kisspeptin-54 detection by tandem mass spectrometry

#166
20150111777
2015-04-23

BIOMARKER FOR EARLY NEURODEGENERATION DETECTION

#167
20150099651
2015-04-09

METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS

#168
20150094218
2015-04-02

METHOD AND KIT FOR DETECTION OF ANTI-BETA AMYLOID ANTIBODIES

#169
20150072360
2015-03-12

BIOMARKERS OF PULMONARY HYPERTENSION

#170
20150064801
2015-03-05

Method for producing reagent for antibody detection and use thereof

#171
20150044704
2015-02-12

Monoclonal antibodies and diagnostic uses thereof

#172
20150037353
2015-02-05

METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2

#173
20150018285
2015-01-15

ANTAGONISTS OF Bcl-2 AND USES THEREOF IN INDUCTION OF APOPTOSIS

#174
20150011594
2015-01-08

BIN1 expression as a marker of cancer

#175
20140378536
2014-12-25

Transcriptional repression leading to parkinson's disease

#176
20140162952
2014-06-12

ERAP1-derived peptide and use thereof

#177
20130165627
2013-06-27

Kisspeptin-54 detection by tandem mass spectrometry

#178
20130129736
2013-05-23

ASPP2 splicing variant

#179
20130064830
2013-03-14

Antibodies specific for sclerostin and methods for increasing bone mineralization

#180
20130064829
2013-03-14

Antibodies specific for sclerostin and methods for increasing bone mineralization

#181
20130053415
2013-02-28

Combination methods for treatment of disease

#182
20130029359
2013-01-31

Monoclonal antibodies and diagnostic uses thereof

#183
20120321636
2012-12-20

Antibodies specific for sclerostin and methods for increasing bone mineralization

#184
20120258133
2012-10-11

Construct for producing empty virus capsids

#185
20120231471
2012-09-13

Marker associated with non-alcoholic steatohepatitis

#186
20120220532
2012-08-30

METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2

#187
20120178088
2012-07-12

Tumor suppressor killin

#188
20120129200
2012-05-24

Prodefensin-A6 assay method for the in vitro diagnosis of colorectal cancer

#189
20120128690
2012-05-24

Methods for determining agents that treat or prevent obesity and/or obesity related diseases and methods for treatment therewith

#190
20120122958
2012-05-17

Transcriptional repression leading to Parkinson's disease

#191
20120121575
2012-05-17

Prohibitin as target for cancer therapy

#192
20120015387
2012-01-19

MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT

#193
20110306063
2011-12-15

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

#194
20110275134
2011-11-10

Arrestin biosensor

#195
20110237461
2011-09-29

USING PHAGE EPITOPES TO PROFILE THE IMMUNE RESPONSE

#196
20110224088
2011-09-15

Biomarkers for subtypes of cervical cancer

#197
20110206678
2011-08-25

Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization

#198
20110206677
2011-08-25

ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION

#199
20110195453
2011-08-11

Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization

#200
20110195078
2011-08-11

TAT-BASED IMMUNOMODULATORY COMPOSITIONS AND METHODS FOR THEIR DISCOVERY AND USE

#201
20110183333
2011-07-28

Method for prediction of the progression risk of tumors

#202
20110171171
2011-07-14

BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS

#203
20110158953
2011-06-30

TUMOR SUPPRESSION THROUGH PLEXIN C1

#204
20110135629
2011-06-09

EYA2S As Modifiers of the PTEN/AKT Pathway and Methods of Use

#205
20110118192
2011-05-19

METHODS AND COMPOSITIONS FOR TREATING T-CELL LEUKEMIA

#206
20110104722
2011-05-05

Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

#207
20110054001
2011-03-03

Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3

#208
20110044908
2011-02-24

Methods and compositions for treating and identifying compounds to treat age-related macular degeneration

#209
20100291242
2010-11-18

ANTAGONIST AGAINST TOLERANCE TO ANTICANCER DRUGS

#210
20100261778
2010-10-14

Tumor Suppressor Killin

#211
20100196275
2010-08-05

Methods and products for neutralizing the harmful effects of combustion products

#212
20100183583
2010-07-22

GALK1S AS MODIFIERS OF THE PTEN/AKT PATHWAY AND METHODS OF USE

#213
20100122354
2010-05-13

CDC6S AS MODIFIERS OF THE PTEN/AKT PATHWAY AND METHODS OF USE

#214
20100034744
2010-02-11

Method for screening anti-HIV Drugs and a diagnostic method of AIDS

#215
20100028882
2010-02-04

METHODS FOR DIAGNOSING OSTEOARTHRITIS

#216
20100009392
2010-01-14

Use of melanoma inhibitory activity (MIA) protein as an early indicator for therapeutic response in melanoma

#217
20090326053
2009-12-31

DIAGNOSTIC USES OF FOLLISTATIN-LIKE 1

#218
20090297543
2009-12-03

Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof

#219
20090220572
2009-09-03

Injectable Combination Therapy for Eye Disorders

#220
20090215084
2009-08-27

B7-H1 AND B7-H4 IN CANCER

#221
20090149413
2009-06-11

RORS as modifiers of the p21 pathway and methods of use

#222
20090148868
2009-06-11

JAB1 as a prognostic marker and a therapeutic target for human cancer

#223
20090117118
2009-05-07

Immunogenic peptides derived from sclerostin

#224
20090104193
2009-04-23

SEMA4D in cancer diagnosis, detection and treatment

#225
20090098537
2009-04-16

Biomarker for sensitivity to mTOR inhibitor therapy in kidney cancer

#226
20090098054
2009-04-16

Methods and compositions relating to promoter regulation by MUC1 and KLF proteins

#227
20080299560
2008-12-04

Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof

#228
20080280769
2008-11-13

Selective and dual-action p53/MDM2/MDM4 antagonists

#229
20080249036
2008-10-09

Antagonist Against Tolerance to Anticancer Drugs

#230
20080249012
2008-10-09

Increasing life span by modulation of Smek

#231
20080241144
2008-10-02

Prohibitin as Target for Cancer Therapy

#232
20080193954
2008-08-14

Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2

#233
20080166354
2008-07-10

SUPPRESSION OF INHIBITORS

#234
20080155703
2008-06-26

Tat-based immunomodulatory compositions and methods of their discovery and use

#235
20080045443
2008-02-21

Compositions for Inhibiting plexin-A1-DAP12 interactions and Methods of Treating Inflammatory, Autoimmune or Bone Resorption Diseases Using the Same

#236
20070238654
2007-10-11

Methods of treating age-related macular degeneration by compstatin and analogs thereof

#237
20070237747
2007-10-11

Method for Increasing the Yield of Proliferating Primary Keratinocytes

#238
20070218493
2007-09-20

Diagnostic marker for interferon responsiveness in multiple sclerosis

#239
20070178531
2007-08-02

Rabbit monoclonal antibodies against mouse/human Id3 proteins

#240
20070141649
2007-06-21

Loc169505 as modifiers of the apc and axin pathways and methods of use

#241
20070141648
2007-06-21

Flj10607 as modifier of the axin pathway and methods of use

#242
20070122830
2007-05-31

Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance

#243
20070117100
2007-05-24

Biomarker for determining predisposition and/or prognosis of hepatocellular carcinoma

#244
20070111267
2007-05-17

Method of determining efficacy of anticancer drug and determination kit therefor

#245
20070105141
2007-05-10

Use of azetidinone compounds

#246
20070072218
2007-03-29

Tumor suppressor Killin

#247
20070072210
2007-03-29

USE OF BRCA1-ASSOCIATED PROTEIN TO TREAT AND SCREEN FOR DNA DAMAGE AND TO IDENTIFY THERAPEUTICS THAT PROMOTE A DNA DAMAGE RESPONSE

#248
20070054852
2007-03-08

Compositions and methods of use of Semaphorin 3F and antagonists thereof in the stimulation of neuromuscular regeneration and treatment of muscular diseases

#249
20070042428
2007-02-22

TREATMENT OF PROLIFERATIVE DISORDERS

#250
20070010433
2007-01-11

Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease

#251
20060101530
2006-05-11

Rors as modifiers of the p21 pathway and methods of use

#252
20060035280
2006-02-16

Screening methods for inhibitors of protein-protein binding interactions

#253
20060019314
2006-01-26

Increasing life span by modulation of Smek

#254
20050266406
2005-12-01

Maxs as modifiers of the axin pathway and methods of use

#255
20050208568
2005-09-22

Use of azetidinone compounds

#256
20050208482
2005-09-22

Tat-based immunomodulatory compositions and methods for their discovery and use

#257
20050202517
2005-09-15

Monoclonal antibodies against human apoptosis inhibitory protein NAIP and method for assaying the NAIP

#258
20050176013
2005-08-11

Pappss as modifiers of the axin pathway and methods of use

#259
20050163779
2005-07-28

Smooth muscle growth inhibitory composition, diagnostic method for arteriosclerosis, and kit therefor

#260
20050106683
2005-05-19

Antibodies specific for sclerostin and methods of screening and use therefor

#261
20050069918
2005-03-31

JAB1 as a prognostic marker and a therapeutic target for human cancer

#262
20050053592
2005-03-10

Tumor suppressor designated Hippo

#263
20050048503
2005-03-03

Human ARL-related gene variants associated with cancers